Characteristics | Mean or Case Number (%) |
---|---|
Age (years) at diagnosis | |
  Mean | 47.3 |
  Range | 24–75 |
Menopausal status at diagnosis | |
  Premenopausal | 75 (47.2) |
  Postmenopausal | 84 (52.8) |
HR status | |
  Negative | 105 (66.0) |
  Positive | 54 (34.0) |
Number of metastatic sites | |
  < 2 | 91 (57.2) |
  ≥ 2 | 68 (42.8) |
Brain metastases | |
  Yes | 37 (23.3) |
  No | 122 (76.7) |
Visceral metastasesa | |
  Yes | 101 (63.5) |
  No | 58 (36.5) |
Prior trastuzumab treatment | |
  Adjuvant setting only | 52 (32.7) |
  Adjuvant and metastatic setting | 25 (15.7) |
  Metastatic setting only | 82 (51.6) |
Duration of previous trastuzumab | |
  < 6 months | 71 (44.7) |
  ≥ 6 months | 88 (55.3) |
Chemotherapy regimens with Lapatinib | |
  Capecitabine | 108 (67.9) |
  Vinorelbine | 51 (32.1) |